ArticleOncoTargets and therapy2019
Metabolomics: a promising diagnostic and therapeutic implement for breast cancer.
Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- Unveiling the anticancer potential of medicinal plants: metabolomics and analytical tools in phytomedicine.Molecular diversity · 2026Review
- Precise metabolomics identifies glycolysis-related pyruvate kinase M activity as regulator of the S-phase-specific radiation response in triple-negative breast cancer cells.Cell communication and signaling : CCS · 2026Article
- Obesity, chronic breast inflammation and carcinogenesis: Molecular pathways and clinical implications (Review).International journal of oncology · 2026Review
- Metabolomic Analysis of Breast Cancer in Colombian Patients: Exploring Molecular Signatures in Different Subtypes and Stages.International journal of molecular sciences · 2025Article
- Deep learning-based computational approach for predicting ncRNAs-disease associations in metaplastic breast cancer diagnosis.BMC cancer · 2025Article
- Metabolomic Profiling of Disease Progression Following Radiotherapy for Breast Cancer.Cancers · 2025Article
- Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics.Breast cancer research and treatment · 2024Article
- Metabolomics and Proteomics in Prostate Cancer Research: Overview, Analytical Techniques, Data Analysis, and Recent Clinical Applications.International journal of molecular sciences · 2024Review
- PdJournal of medicinal chemistry · 2024Article
- Profiling of serum metabolome of breast cancer: multi-cancer features discriminate between healthy women and patients with breast cancer.Frontiers in oncology · 2024Article
- Review
- GPR81-mediated reprogramming of glucose metabolism contributes to the immune landscape in breast cancer.Discover oncology · 2023Article
- Metabolomic Signatures of Scarff-Bloom-Richardson (SBR) Grade in Non-Metastatic Breast Cancer.Cancers · 2023Article
- Microbiome Dysbiosis Shows Strong Association of Gut-Derived Altered Metabolomic Profile in Gulf War Chronic Multisymptom Illness Symptom Persistence Following Western Diet Feeding and Development of Obesity.International journal of molecular sciences · 2023Article
- Article
- Association of serum metabolome profile with the risk of breast cancer in participants of the HUNT2 study.Frontiers in oncology · 2023Article
- A non-invasive method for concurrent detection of early-stage women-specific cancers.Scientific reports · 2022Article
- Article
- Metabolic Profiling of Neocortical Tissue Discriminates Alzheimer's Disease from Mild Cognitive Impairment, High Pathology Controls, and Normal Controls.Journal of proteome research · 2021Article
- Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most commonly diagnosed cancer among women and the leading cause of cancer death. Despite the advent of numerous diagnosis and treatment methods in recent years, this heterogeneous disease still presents great challenges in early diagnosis, curative treatments and prognosis monitoring. Thus, finding promising early diagnostic biomarkers and therapeutic targets and approaches is meaningful. Metabolomics, which focuses on the analysis of metabolites that change during metabolism, can reveal even a subtle abnormal change in an individual. In recent decades, the exploration of cancer-related metabolomics has increased. Metabolites can be promising biomarkers for the screening, response evaluation and prognosis of BC. In this review, we summarized the workflow of metabolomics, described metabolite signatures based on molecular subtype as well as reclassification and then discussed the application of metabolomics in the early diagnosis, monitoring and prognosis of BC to offer new insights for clinicians in breast cancer diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.